Objective — to evaluate the efficacy of Panavir used in combination therapy for the prevention of fetal loss in women with recurrent miscarriage of infectious genesis. Subject and methods. A study group consisted of 42 women aged 21—39 years with chronic cytomegalovirus (CMV) infection who suffered from recurrent miscarriage and were followed up by miscarriage physicians at the women’s health clinics and at the R.P. Askerkhanov Medical Center, Makhachkala. At the stage of pregravid preparation, the study group patients received immunomodulatory and antiviral therapy with Panavir (5 intravenous infusions per cycle). Therapeutic efficiency was monitored using the polymerase chain reaction assay (PCR) of CMV DNA and the enzyme immunoassay of specific antibody titers. After 1.8 years of the performed therapy with Panavir, pregnancy occurred in 18 patients (Group 1) who had received its repeated treatment cycle as part of combination therapy at 16—20 weeks’ gestation. A comparison group (Group 2) comprised 30 pregnant women with chronic CMV infection and a history of recurrent miscarriage who had undergone traditional pregravid preparation and conventional treatment during pregnancy. Results. PCR diagnosis established that only 17 patients from the study group had CMV monoinfection and the mixed flora represented by different pathogen species was identified in the other cases. Forty Panavir-treated patients showed a more than 2-fold reduction in specific immunoglobulin titers; 6 months following treatment, the specific antibody titers significantly increased in none patients. Analysis of the course of pregnancy, labor, delivery, postpartum, and perinatal outcomes in Groups 1 and 2 patients indicated that the patients with chronic CMV infection were frequently observed to have complicated pregnancy (failure to carry to or bear at full term), pathologic labor, and postpartum infectious complications. The use of Panavir at the stage of pregravid preparation and in the second trimester of pregnancy could considerably improve perinatal outcomes: the majority of babies were born in satisfactory condition; there were solitary minor forms of neonatal infection, neither cases of generalized forms of CMV infection nor perinatal losses. Conclusion. The use of Panavir in a package of measures during pregravid preparation and in the second trimester of pregnancy results in a reduction in the frequency of pregnancy complications and improves perinatal outcomes. The authors declare no conflicts of interest.